no meal planning, macro tracking, or other health features Limited microdosing support: Not designed for users exploring split-dosing or alternative dosing protocols No schedule sharing: Can't generate shareable links to show your dosing protocol to others Data sync issues: Users report slow data loading and multi-device sync limitations No retatrutide focus: Limited support for the emerging triple-agonist medication Pricing context: Shotsy's annual price jumped from $29.99 to $49.99 after their February 2025 funding round
Step-by-Step Tips to Reduce Side Effects You cannot remove all side effects, but you can make them easier to live with
Potential risks include overlapping side effects or dosage adjustments
Thats why BHU makes sure that protein bars dont just look good on paper
doi: 10.1128/MCB.00256-14 66 AkbariPGilaniASosinaOKosmickiJAKhrimianLFangYYet al
Key Point: Important Update: FDA Ruling on Compounded GLP-1s As of March 2025, the FDA has declared the shortages of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to be resolved
